Verve Therapeutics (VERV) Conference February 05, 2025 09:00 AM ET Company Participants Sekar Kathiresan - Co-Founder, CEO & Director Operator Well, good morning, everybody. Thanks for joining us here at Guggenheim's SMIDCAP biotech conference. We sort of target companies below the kind of $12,000,000,000 threshold for this conference because these tend to be the companies that actually have the highest returns, in biotech overall. So it's a great opportunity to be joined here this morning by Verve Therapeu ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Verve Therapeutics, Inc. related to self-dealing, which may entitle shareholders to damages and corporate governance reforms [1]. Group 1 - The investigation by Kuehn Law focuses on whether certain officers and directors of Verve Therapeutics engaged in self-dealing that could harm shareholders [1]. - Shareholders of Verve Therapeutics may have the right to seek damages and advocate for changes in corporate governance as a result of the investigation [1]. - Long-term shareholders are encouraged to contact Kuehn Law for a free consultation regarding their rights and potential claims [2]. Group 2 - The firm emphasizes the importance of shareholder participation in maintaining the integrity and fairness of financial markets [3]. - Kuehn Law offers to cover all case costs and does not charge its investor clients, highlighting a commitment to supporting shareholders [2]. - The firm urges shareholders to act quickly due to potential time limitations on enforcing their rights [2].

Company Overview - Verve Therapeutics is a clinical-stage company focused on developing a new class of genetic medicines aimed at treating cardiovascular disease, transitioning from chronic therapies to single-course gene editing medicines [3] - The company is publicly traded on Nasdaq under the ticker symbol VERV [3] Lead Programs - The lead programs include VERVE-102, VERVE-201, and VERVE-301, which target key cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a) [3] - VERVE-102 aims to permanently turn off the PCSK9 gene in the liver, initially targeting heterozygous familial hypercholesterolemia (HeFH) and eventually patients with established atherosclerotic cardiovascular disease (ASCVD) [3] - VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, focusing on refractory hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [3] - VERVE-301 targets the LPA gene to reduce Lp(a) levels, which is an independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis [3] Upcoming Events - Sekar Kathiresan, M.D., co-founder and CEO of Verve Therapeutics, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 9 a.m. ET in New York [1] - A live webcast of the event will be available on the company's investor section of the website and will be archived for 90 days [2]

Company Overview - Verve Therapeutics (VERV) shares increased by 18.7% to close at $7.80, with notable trading volume compared to typical sessions, and a 13.9% gain over the past four weeks [1][2] Clinical Pipeline - Investor optimism is high regarding Verve's clinical-stage pipeline, particularly for VERVE-102, which is in early-stage studies for heterozygous familial hypercholesterolemia and premature coronary artery disease, with initial data expected in Q2 2025 [2] - Verve is also developing two other early-stage candidates: VERVE-201 for refractory hypercholesterolemia and VERVE-301 for various cardiovascular diseases [2] Financial Expectations - The company is projected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -4.4%, while revenues are expected to reach $6.87 million, a 33.7% increase from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Verve Therapeutics is part of the Zacks Medical - Drugs industry, where Karyopharm Therapeutics (KPTI) closed 3% lower at $0.67, despite a 15.4% return over the past month [4] - Karyopharm's consensus EPS estimate has decreased by 27.5% over the past month to -$0.26, showing a year-over-year change of +27.8%, and it currently holds a Zacks Rank of 4 (Sell) [5]

Core Insights - Verve Therapeutics is advancing a new class of genetic medicines targeting cardiovascular diseases, with significant milestones expected in 2025 [2][3][4] Pipeline Updates - Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is anticipated in the second quarter of 2025 [4][5] - The Heart-2 trial includes patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD), with dosing having progressed to the 0.6 mg/kg cohort [4][5] - VERVE-301 has been nominated as a development candidate targeting the LPA gene, with a milestone payment expected from Eli Lilly [2][6] - The company plans to initiate a Phase 2 clinical trial for the PCSK9 program in the second half of 2025 [5] Financial Position - Verve Therapeutics is well-capitalized, with a cash runway extending into mid-2027, supported by existing cash and a milestone payment from Eli Lilly [2][6] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [2][7] Company Overview - Verve Therapeutics is focused on developing genetic medicines that aim to provide lifelong cholesterol lowering after a single treatment, targeting key drivers of high cholesterol [3][8] - The lead programs include VERVE-102, VERVE-201, and VERVE-301, which address LDL-C, remnant cholesterol, and Lp(a) respectively [8][9]

Core Insights - Verve Therapeutics is advancing a new class of genetic medicines targeting cardiovascular disease, with significant milestones expected in 2025 [1][2][3] Pipeline Updates - Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is expected in the second quarter of 2025 [1][3] - Dosing in the Heart-2 trial has progressed to the 0.6 mg/kg cohort, with previous cohorts showing no serious adverse events [3][4] - The Heart-2 trial includes patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD) [3][8] - VERVE-301 has been nominated as a development candidate targeting the LPA gene, with a milestone payment from Eli Lilly expected [1][5][7] Financial Position - Verve is well-capitalized, with cash runway extending into mid-2027, supported by existing cash and expected milestone payments [1][5] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [1][6]

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 3 ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.71%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.68 per share when it actually produced a loss of $0.59, delivering a surprise of 13.24%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4 ...

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3; Regulatory clearances in Australia, Canada, and the U.K. Cash, cash equivalents, and marketable securities of $539.9 million; cash runway through 2 ...